Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 10534275.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.
Medical subject headings
- Adjuvants, Immunologic
- BCG Vaccine
- Multiple Sclerosis